Table 1 (abstract P392). Cases with receiving biological treatments (n=80)

Sex

%48.8 male (n=39)      %51.2 female (n=41)

Onset of Symptoms (year)

4.41 (0.16-17)

Diagnosis time (year)

7 (0.66-16)

Family History of Rheumatic Disorders

%26.25 (n=21)

Receiving Steroid Treatment

%37.5 (n=30)

Types of MEFV mutations

27.5% (n=22) MEFV mutation (+)

63.6% (n= 14) exon-10 mutations

54.5% (n=12) have M694V mutations

31.8% (n=7) have M694V homozygous

ANA positivity

27.5 (n=22)

Infection and malignancy after treatment

Tuberculosis infection (n=1)

Varicella zoster (n=1)

Recurrent upper respiratory tract infections (n=2)

Acute Lymphoblastic Leukaemia (n=1)

Need of Tuberculosis Prophylaxis

%26.25 (n=21)

Mean Remission Time (months)

2.00 (1-18)